All News

stop.smoking.jpg

Implementing Smoking Cessation Programs

d Jack Cush, MD

Rheumatologists are keen to the effects of smoking (increased arthritis risk, worse outcomes, blunted DMARD responses, added cardiopulmonary risks), but often do not have the resources or plan to encourage or implement smoking cessation from the rheumatology clinic. A new study details the success of a rheumatology staff‐driven protocol, Quit Connect, to increase the rate of electronic referrals to free, state‐run tobacco quit lines.

Read Article
medical.problems.jpg

Rheumatology Care Derailed by COVID-19

d Jack Cush, MD

A survey study from the  ArthritisPower PPRN or CreakyJoints database shows that during the COVID-19 pandemic patient care was substantially affected in unforeseen ways.

Read Article
COVID19.needles.Rx_.jpg

Reactogenicity Following mRNA COVID-19 Vaccines

d Jack Cush, MD

JAMA has published the real-world reporting of mRNA vaccine side effects (reactogenicity) gathered from CDC V-safe Surveillance system and shows that local and systemic reactions were often mild and transient and most commonly seen during the first day following their second dose.

Read Article
cushknees1.jpg

Cost Efficacy of Knee Replacement in Obese Osteoarthritis

d Jack Cush, MD

Total knee replacement (TKR) in obese patients with end-stage knee osteoarthritis appears to be a beneficial and cost-effective strategy for treating. The only potential limitation is a greater risk for adverse events in those with a body mass index (BMI) of 40 kg/m2 or greater.

Read Article
PSS.hands_.Raynauds.jpg (keep)

Rituximab in Systemic Sclerosis?

d Jack Cush, MD

No drug is FDA approved to manage the skin or joint complaints of systemic sclerosis (SSc); a recent metanalysis suggests that rituximab may improve skin score and disease activity indices (DAS, mRSS) while stabilizing organ involvement in SSc patients.

Read Article
Axial Involvement in Spondyloarthritis: A Patient-Centered Exploration Sponsored by Novartis Medical Affairs Listen to Ethan Craig, MD, MPH discuss 3 of his patient cases to identify and differentiate axial involvement within the spectrum of SpA. https://t.co/o2q5pTP3WD https://t.co/su41ECWslk

Links:

Dr. John Cush RheumNow ( View Tweet)
Algorithm for the diagnostic approach of patients with joint pain - developed by PANLAR rheumatologists from 18 countries using a delphi method. Open read https://t.co/GyyfStD8Xi

Links:

Dr. John Cush RheumNow ( View Tweet)

From @KDAO2011-- "Is it better to taper the steroids or leave it? SEMIRA study. Tapering off low dose steroids cause more flares and more treatment side effects. Dr. Buttgereit says keep your low dose steroids (prednisone 5 mg/day or less) https://t.co/RAYkVxGO9N #RNL2021"

Links:

Dr. John Cush RheumNow ( View Tweet)

CDC updates its COVID Comorbid Dz list to include type 1 diabetes (& NIDDMA), mod-severe asthma, liver Dz, dementia , stroke/cerebrovascular disease, HIV infxn, cystic fibrosis, obesity, substance use disorders (NOT ARTHRITIS, PSORIASIS) https://t.co/LbVMVGf4IR

Links:

Dr. John Cush RheumNow ( View Tweet)

Cox-2 inhibition (Celebrex 200 mg bid) added to standard chemoRx (FolFox) in pts w/ stage III colon cancer failed to improve survival at 3 yrs - DB, RCT vs placebo; 3 yrs Dz free survival was Celecoxib 76% vs PBO 73% (HR 0.89; 95% CI, 0.76-1.03; P = .12) https://t.co/81L33QLa9d https://t.co/EQXgwMcgtd

Links:

Dr. John Cush RheumNow ( View Tweet)
News Feature: US Senate Introduces the Safe Step Act #RheumNow https://t.co/5SPTIXnJCS https://t.co/DtmrlJMXL9

Links:

Dr. John Cush RheumNow ( View Tweet)
Beijing study of 207 RA patients starting DMARD and steroids (GC) shows after 3 years only 59% D/C GC (mean was 24 mos). Odds of stopping GC were 10% @ 6mos, 27% @Yr1, 48% @Yr 2 and 59% at 3 years. https://t.co/E2RchB9IAs https://t.co/uDEAqaM8GC

Links:

Dr. John Cush RheumNow ( View Tweet)
Interesting case with unilateral sacroilitis - potential mimics include: Paget disease, diffuse idiopathic skeletal hyperostosis, sarcoidosis, infections [3], and also bone and hematologic tumors. What did this man have? https://t.co/Uu0kJxeJtn

Links:

Dr. John Cush RheumNow ( View Tweet)

New podcast up! Download wherever podcasts are available. Upadacitinib Wins in PsA Dr Jack Cush reviews the news and Journal reports and takes "Back Talk" questions from viewers. https://t.co/ZMAUgn10dU https://t.co/QTDqZW3GgG

Links:

Dr. John Cush RheumNow ( View Tweet)
Another study suggests poorer outcomes in Rheum pts on Rituximab. French Cohort study of 1090 inflammatory rheumatic MSK pts -13% w/ severe COVID-19 & 8% who died. 63 RTX pts had more severe disease, longer hosp stays & more death (21% vs 7%) https://t.co/5UCvFeVWRS

Links:

Dr. John Cush RheumNow ( View Tweet)

#RNL2021 insight from the Lupus panel--originally tweeted by @KDAO2011 "Lupus panniculitis feels like wood: mummified degenerative fat replaced by fibers " #RheumNow

Dr. John Cush RheumNow ( View Tweet)

Interestng overview/read on the Inflammasome - its history, clinical targeting and new inflammasome (NLRP3) inhibitors in development by pharma. https://t.co/DEdP09GZd7

Links:

Dr. John Cush RheumNow ( View Tweet)

Are you signed up for the RheumNow daily newsletter? Head over to RheumNow and sign up to have the news delivered to your inbox daily. https://t.co/HSBjF6ySNv

Links:

Dr. John Cush RheumNow ( View Tweet)

#RNL2021 coverage from @uptoTate "Dr. Robert Wang: 91% of uveitis is non-infectious and located in the front of the eye - "anterior uveitis/iritis." 50% of anterior uveitis patients are +HLA B27! " #RheumNowLive

Dr. John Cush RheumNow ( View Tweet)

News Feature: Upadacitinib Clinical Efficacy in Psoriatic Arthritis https://t.co/gdAnqEFk3n https://t.co/PNYwhRFTEK

Links:

Dr. John Cush RheumNow ( View Tweet)
×